William Hrushesky to Cisplatin
This is a "connection" page, showing publications William Hrushesky has written about Cisplatin.
Connection Strength
0.848
-
A recent illustration of some essentials of circadian chronotherapy study design. J Clin Oncol. 2004 Jul 15; 22(14):2971-2; author reply 2972.
Score: 0.213
-
Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995 Apr; 95(4):1650-9.
Score: 0.112
-
Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst. 1989 Jan 18; 81(2):135-45.
Score: 0.073
-
Cisplatin neurotoxicity: failure to demonstrate vitamin B12 inactivation. Cancer Treat Rep. 1985 Apr; 69(4):453-5.
Score: 0.056
-
Lack of age-dependent cisplatin nephrotoxicity. Am J Med. 1984 Apr; 76(4):579-84.
Score: 0.052
-
Circadian time dependence of cisplatin urinary kinetics. Clin Pharmacol Ther. 1982 Sep; 32(3):330-9.
Score: 0.047
-
Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. Cancer Res. 1982 Mar; 42(3):945-9.
Score: 0.045
-
Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res. 2001 Mar; 92(3):328-36.
Score: 0.042
-
Erythropoietin usage in patients with cancer. Cancer J Sci Am. 1995 Nov-Dec; 1(4):243-6.
Score: 0.029
-
High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancer. Cancer Treat Rep. 1987 Oct; 71(10):915-9.
Score: 0.017
-
High-dose intensity systemic therapy of metastatic bladder cancer. J Clin Oncol. 1987 Mar; 5(3):450-5.
Score: 0.016
-
Chemotherapy-induced vomiting: circadian drug timing as a source of predictable within-patient variability. Cancer Treat Rep. 1986 Nov; 70(11):1347-8.
Score: 0.016
-
Advanced transitional cell bladder cancer: a treatable disease. Semin Surg Oncol. 1986; 2(2):76-89.
Score: 0.015
-
Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences. Chronobiol Int. 1986; 3(1):55-64.
Score: 0.015
-
Lack of antiemetic effect of high-dose metoclopramide. J Clin Oncol. 1985 Sep; 3(9):1273-6.
Score: 0.014
-
Circadian timing of cancer chemotherapy. Science. 1985 Apr 05; 228(4695):73-5.
Score: 0.014
-
Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984 Jul; 34(7):934-8.
Score: 0.013
-
Circadian mesor of recumbent pulse--cost-effective predictor of doxorubicin-induced congestive heart failure. Chronobiol Int. 1984; 1(1):59-66.
Score: 0.013
-
The clinical application of chronobiology to oncology. Am J Anat. 1983 Dec; 168(4):519-42.
Score: 0.013
-
Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism. Cancer Treat Rep. 1982 Nov; 66(11):1933-8.
Score: 0.012
-
Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration. Eur J Cancer Clin Oncol. 1982 May; 18(5):471-7.
Score: 0.011
-
Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res. 1982 Mar; 42(3):950-5.
Score: 0.011